Cantillon Daniel J, Gorodeski Eiran Z, Caccamo Marco, Smedira Nicholas G, Wilkoff Bruce L, Starling Randall C, Saliba Walid
Department of Cardiovascular Medicine, Cleveland Clinic, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland, OH 44195, USA.
J Heart Lung Transplant. 2009 Aug;28(8):791-8. doi: 10.1016/j.healun.2009.04.034.
Prior studies have yielded inconsistent results on bradyarrhythmias requiring a permanent pacemaker (PPM) after cardiac transplant. This study evaluated the predictors for PPM requirement, long-term outcomes, and influence of implant timing and device programming on prognosis after cardiac transplant.
This study prospectively evaluated 1,307 recipients from 1985 to 2007 at Cleveland Clinic by structured follow-up and compared the outcomes of patients with and without bradyarrhythmias requiring PPM after transplantation. The primary end point was all-cause mortality or retransplant.
Recipients, aged 50 +/- 15 years (donors, 33 +/- 14 years), were monitored 82 +/- 59 months, with PPM indicated in 106 (8.1%), including 61 (57.5%) early and 44 (42.5%) late. Biatrial technique strongly predicted PPM requirement (OR [odds ratio], 2.61; 95% confidence interval [CI], 1.63-4.20; p < 0.001), and survival/retransplant outcomes were comparable between those with early, late, and no PPM requirement: 5-year primary event-free rate was 80.4% (early) vs 72.6% (late; p = 0.480) and 80.4% (early) vs 73.2% (none, p = 0.550) and 72.6% (late) vs 73.2% (none; p = 0.960). Excess atrial fibrillation was noted among PPM recipients (PPM, 12.3% vs no PPM, 6.3%; p = 0.02) with high initial DDD programming in 92.5% (98 of 106). Sinus rhythm with intact atrioventricular conduction at 6 months was present in 69 (85%), yet 67 (67%) remained DDD programmed, with mean 26.0% +/- 38.0% right ventricular pacing.
No excess mortality is associated with a PPM after cardiac transplantation, and biatrial technique strongly predicts PPM requirement. Increased atrial fibrillation among PPM recipients may be related to right ventricular stimulation with dual-chamber pacing.
先前的研究对于心脏移植后需要永久起搏器(PPM)的缓慢性心律失常得出了不一致的结果。本研究评估了PPM需求的预测因素、长期预后,以及植入时机和设备程控对心脏移植后预后的影响。
本研究通过结构化随访对1985年至2007年在克利夫兰诊所的1307名受者进行了前瞻性评估,并比较了移植后有或无需要PPM的缓慢性心律失常患者的预后。主要终点是全因死亡率或再次移植。
受者年龄为50±15岁(供者为33±14岁),随访82±59个月,106名(8.1%)患者需要PPM,其中61名(57.5%)为早期,44名(42.5%)为晚期。双心房技术强烈预测PPM需求(比值比[OR],2.61;95%置信区间[CI],1.63 - 4.20;p < 0.001),早期、晚期和无PPM需求患者的生存/再次移植结局相当:5年无主要事件发生率为80.4%(早期)对72.6%(晚期;p = 0.480),80.4%(早期)对73.2%(无PPM需求,p = 0.550),72.6%(晚期)对73.2%(无PPM需求;p = 0.960)。PPM受者中房颤发生率较高(PPM受者为12.3%,无PPM受者为6.3%;p = 0.02),92.5%(106名中的98名)初始DDD程控较高。6个月时69名(85%)患者为窦性心律且房室传导完整,但67名(67%)仍为DDD程控,平均右心室起搏比例为26.0%±38.0%。
心脏移植后PPM与额外死亡率无关,双心房技术强烈预测PPM需求。PPM受者房颤增加可能与双腔起搏刺激右心室有关。